Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
716 (USA) · Dr. Ito
consented 2012-12-14
AEs
2
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild COGNITIVE DISORDER — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-14 (study day 1.0); relationship: NONE
moderate
assessed
Moderate PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-15 (study day 2.0); relationship: PROBABLE
Data queries
No data queries.